Ozmosi | Dacomitinib Drug Profile

Product Description

Dacomitinib is a multi-kinase receptor inhibitor used in the therapy of cases of non-small cell lung cancer that harbor activating mutations in the epidermal growth factor receptor gene (EGFR). Dacomitinib is associated with high rate of transient serum aminotransferase elevations during therapy but has not been linked to instances of clinically apparent acute liver injury. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Dacomitinib)

Mechanisms of Action: TK Inhibitor,EGFR Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Approved

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Dacomitinib

Countries in Clinic: Hong Kong, Korea, Malaysia, Netherlands, Singapore, Thailand

Active Clinical Trial Count: 2

Recent & Upcoming Milestones

Highest Development Phases

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success	Latest Trial Update Date	Data Updated
DRUP	P2	Recruiting	Lymphoma, B-Cell\|Hodgkin Lymphoma\|Vision, Low\|Abnormalities, Multiple\|Multiple Myeloma\|Lymphoma, Non-Hodgkin	2027-09-01	12%	2024-01-25	Primary Endpoints
ATORG-003	P2	Active, not recruiting	Non-Small-Cell Lung Cancer	2026-03-31	12%	2024-06-26	Primary Endpoints\|Treatments

Recent News Events

Date	Type	Title
06/17/2025	News Article	Lung Cancer Research Foundation Announces Request for Proposals Focused on Curing EGFR Mutant Lung Cancers
07/11/2024	News Article	Head and Neck Cancer Treatment Market size is set to grow by USD 7.12 billion from 2024-2028, Increasing incidence of head and neck cancers boost the market, Technavio
10/03/2023	News Article	Lung Cancer Therapeutic Market Is Expected to Grow at A Stable CAGR During the Forecast Period (2023-2030) - Russia-Ukraine War Tracker
08/03/2022	News Article	Amber Specialty Pharmacy Added to Pfizer's Limited Distribution Network for Oncology Portfolio

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Dacomitinib

Alternative Names: dacomitinib, pf-00299804, pf-299, pf299, pf 299, vizimpro Clinical Status: Active Latest Update: 2025-07-09 Latest Update Note: Clinical Trial Update